Skip to main content
Log in

Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The Wilms tumor gene, WT1, is overexpressed not only in leukemias and myelodysplastic syndrome (MDS) but also in various types of solid tumors, including lung and breast cancer, and the WT1 protein is a tumor antigen for these malignancies. In clinical trials of WT1 peptide-based cancer immunotherapy, patients with overt leukemia from MDS or MDS with myelofibrosis were injected intradermally with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Only a single dose of WT1 vaccination resulted in an increase in WT1-specific cytotoxic T-lymphocytes, which was followed by a rapid reduction in leukemic blast cells. Severe leukopenia and local erythema at the injection sites of WT1 peptide were observed as adverse effects.These results have provided us with the first clinical evidence suggesting that WT1 peptide-based immunotherapy is an attractive treatment for patients with leukemias or MDS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus.Cell. 1990;60:509–520.

    Article  CAS  PubMed  Google Scholar 

  2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.Nature. 1990;343:774–778.

    Article  CAS  PubMed  Google Scholar 

  3. Menke AL, van der Eb AJ, Jochemsen AG. The Wilms’ tumor 1 gene: oncogene or tumor suppressor gene.Int Rev Cytol. 1998;181:151–212.

    Article  CAS  PubMed  Google Scholar 

  4. Miwa H, Beran M, Saunders GF. Expression of the Wilms’ tumor gene (WT1) in human leukemias.Leukemia. 1992;6:405–409.

    CAS  PubMed  Google Scholar 

  5. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm’s tumor gene, WT1, in human leukemia cells.Leukemia. 1993;7:970–977.

    CAS  PubMed  Google Scholar 

  6. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.Blood. 1994;84:3071–3079.

    CAS  PubMed  Google Scholar 

  7. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms’ tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells.Leukemia. 1994;8:2138–2143.

    CAS  PubMed  Google Scholar 

  8. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.Leukemia. 1995;9:1060–1067.

    CAS  PubMed  Google Scholar 

  9. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.Blood. 1997;89:1405–1412.

    CAS  PubMed  Google Scholar 

  10. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.Leukemia. 1999;13:393–399.

    Article  CAS  PubMed  Google Scholar 

  11. Sugiyama H. Wilms’ tumor gene WT1: its oncogenic function and clinical application.Int J Hematol. 2001;73:177–187.

    Article  CAS  PubMed  Google Scholar 

  12. Shichishima T, Okamoto M, Ikeda K, et al. HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria.Blood. 2002;100:22–28.

    Article  CAS  PubMed  Google Scholar 

  13. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth.Jpn J Cancer Res. 1999;90:194–204.

    CAS  PubMed  Google Scholar 

  14. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms’ tumor suppressor gene (WT1) predicts poor prognosis in breast cancer.J Clin Cancer Res. 2002;8:1167–1171.

    CAS  Google Scholar 

  15. Oji Y, Miyoshi S, Maeda H, et al. Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers.Int J Cancer. 2002;100:297–303.

    Article  CAS  PubMed  Google Scholar 

  16. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product.Immunogenetics. 2000;51:99–107.

    Article  CAS  PubMed  Google Scholar 

  17. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product.J Immunol. 2000;164:1873–1880.

    CAS  PubMed  Google Scholar 

  18. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination.J Clin Immunol. 2000;20:195–202.

    Article  CAS  PubMed  Google Scholar 

  19. Sugiyama H. Cancer immunotherapy targeting WT1 protein.Int J Hematol. 2002;76:127–132.

    Article  CAS  PubMed  Google Scholar 

  20. Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H. WT1 as a novel target antigen for cancer immunotherapy.Curr Cancer Drug Targets. 2002;2:45–54.

    Article  CAS  PubMed  Google Scholar 

  21. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1.Blood. 2000;95:2198–2203.

    CAS  PubMed  Google Scholar 

  22. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide.Blood. 2000;95:286–293.

    CAS  PubMed  Google Scholar 

  23. Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.Clin Cancer Res. 2002;8:2626–2631.

    CAS  PubMed  Google Scholar 

  24. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.Cancer Immunol Immunother. 2002;51:614–620.

    Article  CAS  PubMed  Google Scholar 

  25. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.Blood. 2000;96:1480–1489.

    CAS  PubMed  Google Scholar 

  26. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freunds’ adjuvant for restricted highrisk melanoma.Clin Cancer Res. 1999;5:2756–2765.

    CAS  PubMed  Google Scholar 

  27. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.Blood. 2002;99:3272–3279.

    Article  CAS  PubMed  Google Scholar 

  28. Gotoh M, Takasu H, Harada K, Yamaoka T. Development of HLAA2402/ Kb transgenic mice.Int J Cancer. 2002;100:565–570.

    Article  CAS  PubMed  Google Scholar 

  29. Mhawech P, Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data.Crit Rev Oncol Hematol. 2001;40:229–238.

    Article  CAS  PubMed  Google Scholar 

  30. Nilsson L, Astrand-Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.Blood. 2000;96:2012–2021.

    CAS  PubMed  Google Scholar 

  31. Jaju RJ, Jones M, Boultwood J, et al. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q-syndrome.Genes Chromosomes Cancer. 2000;29:276–280.

    Article  CAS  PubMed  Google Scholar 

  32. van Lom K, Hagemeijer A, Smit E, Hahlen K, Groeneveld K, Lowenberg B. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage.Leukemia. 1995;9:1818–1821.

    PubMed  Google Scholar 

  33. Miura I, Kobayashi Y, Takahashi N, Saito K, Miura AB. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting.Br J Haematol. 2000;110:876–879.

    Article  CAS  PubMed  Google Scholar 

  34. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.Blood. 2002;100:2132–2137.

    Article  CAS  PubMed  Google Scholar 

  35. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis.Blood. 1996;87:2878–2884.

    CAS  PubMed  Google Scholar 

  36. Inoue K, Tamaki H, Ogawa H, et al. Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells.Blood. 1998;91:2969–2976.

    CAS  PubMed  Google Scholar 

  37. Tsuboi A, Oka Y, Ogawa H, et al. Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF).Leuk Res. 1999;23:499–505.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Haruo Sugiyama.

About this article

Cite this article

Oka, Y., Tsuboi, A., Murakami, M. et al. Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78, 56–61 (2003). https://doi.org/10.1007/BF02983241

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02983241

Key words

Navigation